Defense Contract was Palisade Bio’s largest revenue line in fiscal 2012, bringing in $234.00K of $407.00K (57%).
| Equity Components | FY 2012 |
|---|---|
| Defense Contract | $234.00K |
| Licensing Agreements | $173.00K |
| Total | $407.00K |
Palisade Bio brought in $407.00K from its two revenue lines in fiscal 2012, the year ended December 31, 2012. Defense Contract was the largest at $234.00K (57.5%), ahead of Licensing Agreements at $173.00K (42.5%).
Palisade Bio (PALI) reports its revenue by equity components. In fiscal 2012, Defense Contract was its largest revenue line, bringing in $234.00K (57.5% of the total), followed by Licensing Agreements at $173.00K (42.5%).
Defense Contract was Palisade Bio's largest revenue line in fiscal 2012, bringing in $234.00K, or 57.5% of the $407.00K total across its two revenue lines.
Every figure comes from Palisade Bio's annual financial filings, as reported. Each line keeps the name Palisade Bio gives it, and years follow its fiscal calendar.
Palisade Bio's revenue by equity components goes back to fiscal 2012, with figures through fiscal 2012. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.